摘要
目的探讨脑胶质瘤术后调强放疗联合替莫唑胺化疗的临床效果。方法选取2009年2月~2011年3月我院收治的脑胶质瘤患者78例,随机平均分为两组,每组39例。术后均给予调强放疗,实验组在调强放疗的基础上使用替莫唑胺化疗。对比近、远期临床效果及不良反应。结果实验组调强放疗联合替莫唑胺化疗,有效率为64.1%,疾病控制率为92.3%。对照组有效率为38.5%,疾病控制率为74.4%。两组患者有效率和疾病控制率对比差异有统计学意义（P〈0.05）。实验组半年生存率为76.9%,一年生存率为64.1%;对照组半年生存率为59.0%,一年生存率为35.9%,两组对比均有显著差异（P〈0.05）。实验组不良反应稍高于对照组,但差异无统计学意义（P〉0.05）。结论脑胶质瘤术后联合调强放疗和化疗具有协同效应,提高治疗效果,安全可靠,值得广泛推广。
Objective To investigate the clinical effects of intensity modulated radiotherapy combined with Temozolomide chemotherapy after operation of cerebral glioma.Methods A total of 78 patients with cerebral glioma admitted to our hospital from February 2009 to March 2011 were randomly divided into two groups.Both groups were given intensity modulated radiotherapy and the experiment group was given additional Temozolomide chemotherapy.Short-term and long-term clinical effects and adverse reactions were compared.Results In the experiment group,the effective rate was 64.1% and the disease control rate was 92.3%.In the control group,the effective rate was 38.5% and the disease control rate was 74.4%.The effective rates and the disease control rates were significantly different between the two groups（P 〈0.05）.In the experiment group,the six months survival rate was 76.9% and the one year survival rate was 64.1%,and in the control group,the six months survival rate was 59.0% and the one year survival rate was 35.9%,with significant differences in both rates between the two groups（P 〈0.05）.There were more adverse reactions in the experiment group than in the control group,with no significant difference（P 〈0.05）.Conclusion Intensity modulated radiotherapy combined with Temozolomide chemotherapy after cerebral glioma have synergistic effects,can improve curative effects,is safe and reliable,thereby worthy of wide promotion.
出处
《中国医药导报》
CAS
2012年第21期166-167,共2页
China Medical Herald
关键词
脑胶质瘤
调强放疗
替莫唑胺
Cerebral glioma
Intensity modulated radiotherapy
Temozolomide
